A Phase I clinical trial of TFC-039 for the treatment of Type 2 diabetes
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs TFC-039 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 03 Jul 2019 According to a Sirona Biochem media release, this trial is progressing on schedule with no adverse events.
- 03 Jul 2019 Status changed from planning to recruiting, according to a Sirona Biochem media release.
- 30 Jan 2019 According to a Sirona Biochem media release, the company is planning to meet Wanbang Biopharmaceuticals and anticipate a joint announcement on progress regarding the status of CFDA testing after the Chinese New Year.